SecBot SecBot
PRESS-RELEASE ·Filed Aug 12, 2026

BWAY

BrainsWay
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The raised guidance and strong operating metrics (35% revenue growth, 20% EBITDA margin, record shipments) suggest accelerating commercial momentum. Traders should watch for continued RPO conversion and further reimbursement expansion as catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.60
T+0 close · Aug 12, 2026 · via day close
Latest settled
−36.08%
T+60 · $10.61
Vs SPY
−30.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $16.60entry
  2. T+1 · 3mo ago −0.78%α −1.48% · $16.47
  3. T+5 · 3mo ago −8.61%α −8.17% · $15.17
  4. T+20 · 2mo ago −16.20%α −14.31% · $13.91
  5. T+60 · 12d ago −36.08%α −30.97% · $10.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay reported Q2 2026 revenue of $17.1M (+35% YoY), EPS of $0.07 (GAAP), and raised FY 2026 revenue guidance to $68-70M and Adjusted EBITDA guidance to $13-14M. The record system shipments (125 units, +42% YoY) and RPO growth to $80.4M (+30% YoY) signal strong demand momentum, while operating margin expanded to 14% from 5% YoY. The stock is likely to react positively given the beat on consensus estimates ($0.19 vs $0.07 EPS estimate, though GAAP EPS was $0.07) and raised guidance.

Key Financial Metrics

EPS
$0.07
est $0.07 · 0.0%
Revenue
$17.1M
est $16.5M · +3.6% · +35.4% YoY
Rating
beat
Guidance
$68M-$70M
raised
Gross Margin
74.6%

Key Facts

  • Q2 2026 revenue $17.1M, +35% YoY from $12.6M
  • GAAP EPS $0.07 (basic and diluted), net income $2.7M
  • Adjusted EBITDA $3.5M, +141% YoY, margin 20%
  • Record 125 Deep TMS systems shipped, +42% YoY
  • RPO $80.4M, +30% YoY
  • Raised FY 2026 revenue guidance to $68-70M (from $66-68M)
  • Raised FY 2026 Adjusted EBITDA guidance to $13-14M (from $12-14M)
  • Operating cash flow $6.3M in Q2 2026
  • Cash and equivalents $62.1M as of June 30, 2026

Financial Impact

Revenue beat consensus by $0.6M ($17.1M vs $16.5M est); GAAP EPS $0.07 vs $0.07 consensus (in-line); raised FY guidance implies ~30-34% revenue growth and ~90-100% EBITDA growth YoY

revenueepsadjusted ebitdaoperating margincash flow

Risk Factors

  • Guidance assumes continued reimbursement expansion and utilization growth, which may not materialize if payer coverage slows
  • Competition from other TMS and neurostimulation modalities could pressure market share
  • Dependence on FDA-cleared indications (MDD, OCD, smoking addiction) limits addressable market without new approvals

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3343549

US Market Status

Market Closed · Opens Wed (12h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026